Lung Cancer (NSCLC) Clinical Trials in Guangzhou, Guangdong
18 recruitingGuangzhou, Guangdong, China
Showing 1–18 of 18 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled220 locationsNCT06170788
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 1
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
Squamous Non-Small Cell Lung Cancer (NSCLC)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.150 enrolled1 locationNCT07638891
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled273 locationsNCT07361510
Recruiting
Phase 3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.180 enrolled33 locationsNCT07154706
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 2
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Lung Cancer (NSCLC)
Sun Yat-sen University56 enrolled1 locationNCT07103395
Recruiting
Phase 2
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Lung Cancer (NSCLC)
Sun Yat-sen University32 enrolled1 locationNCT06924398
Recruiting
Phase 2
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Non-small Cell Lung Cancer (NSCLC)
Sun Yat-sen University83 enrolled1 locationNCT06977074
Recruiting
Phase 3
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
Lung Cancer (NSCLC)
Yang Hong360 enrolled1 locationNCT06598527
Recruiting
Phase 2
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
Lung Cancer (NSCLC)
Sun Yat-sen University52 enrolled1 locationNCT06730295
Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Lung CancerLung Cancer (NSCLC)Lung+1 more
The First Affiliated Hospital of Guangzhou Medical University2,500 enrolled1 locationNCT06843707
Recruiting
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Lung Cancer (NSCLC)
Guangdong Provincial People's Hospital120 enrolled1 locationNCT06771960
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 2
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Advanced Non Small Cell Lung Cancer (NSCLC)Third-line and Beyond TherapyRecurrent or Metastatic Lung Cancer+1 more
Li-kun Chen32 enrolled1 locationNCT06728852
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057